▶ IPAMORELIN · SUBTOPIC · DOSING LITERATURE
IPAMORELIN Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of IPAMORELIN. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for IPAMORELIN reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of IPAMORELIN.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for IPAMORELIN of approximately ~2 hours. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of IPAMORELIN. Refer to the original publication for full protocol detail.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998) reports the IPAMORELIN protocol used in Ipamorelin, the first selective growth hormone secretagogue, published in Eur J Endocrinol. PMID 9849822. See the source for the protocol-level dose range, frequency, and duration. link
- Beck DE, Sweeney WB, McCarter MD, et al. (2014) reports the IPAMORELIN protocol used in Safety and pharmacology of ipamorelin in healthy volunteers and postoperative ileus patients, published in J Gastrointest Surg. PMID 25331030. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is the half-life of ipamorelin?
Approximately 2 hours plasma half-life. The pulse-and-decay profile lasts roughly 3-4 hours in published pharmacokinetic studies.
▶ How is ipamorelin dosed in research?
Animal-model and community-reported research protocols use 100-300 mcg per administration, often paired 1:1 by mass with CJC-1295 No DAC, 1-3 times daily, subcutaneous. No human dose is recommended by this wiki.
▶ What are the side effects of ipamorelin?
Mild injection-site reactions, transient hunger (mild ghrelin-receptor activation), rare water retention, rare mild flushing. Cleaner profile than older non-selective GHS like GHRP-6.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Helsinn/Lilly Phase 2 postoperative ileus program discontinued. Research-use only.
WADA · Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25